

Contents

- 11 **Detection of arrhythmias in the active population**
Chairman: *M. Schlepper*
- 12 Symptoms suggesting cardiac arrhythmias. *B.W. Johansson*
- 15 Discussion: *Denolin, Jewitt, Johansson, Kulbertus, Mogensen, Pool, Sandøe, Schlepper, Van Durme, Winkle*
- 17 Cardiac arrhythmias – recording, provocation, transmission. *B. Demaret*
- 22 Discussion: *Campbell, Demaret, Schlepper, Schröder, Slama, Touboul, Winkle*
- 24 Prevalence and variability of cardiac arrhythmias in healthy subjects. *P. Bjerregaard*
- 32 Discussion: *Bjerregaard, Chamberlain, Denolin, Johansson, Robles de Medina, Schröder, Touboul, Vedin, Winkle*
- 35 The incidence and prevalence of bradyarrhythmias. *D.B. Shaw*
- 38 Discussion: *Chamberlain, Gmeiner, Kulbertus, Mogensen, Robles de Medina, Sandøe, Shaw*
- 41 **Significance of arrhythmias in the active population**
Chairman: *H. Kulbertus*
- 42 Significance of supraventricular tachyarrhythmias. *J. Pool*
- 45 Discussion: *Kulbertus, Mogensen, Pool, Shaw, Slama, Winkle*
- 47 Significance of ventricular tachyarrhythmias. *J.A. Vedin, C.-E. Wilhelmsson and J.-G. Fodor*
- 54 Discussion: *Bjerregaard, Johansson, Kulbertus, Mogensen, Olsson, Vedin*
- 56 Significance of bradyarrhythmias. *K. Rasmussen*
- 61 Discussion: *Chamberlain, Jewitt, Johansson, Kulbertus, Mogensen, Rasmussen, Robles de Medina, Schlepper, Shaw, Slama, Winkle*
- 64 Intraventricular conduction defects. *J.C. Roos*
- 72 Discussion: *Campbell, Jewitt, Johansson, Kulbertus, Mogensen, Roos, Sandøe, Schröder, Slama*
- 75 **Management of arrhythmias in the active population**
Chairman: *D.A. Chamberlain*
- 76 The epidemiology of antiarrhythmic drug use. *L. Mogensen*
- 79 Discussion: *Jewitt, Kulbertus, Mogensen, Pool*
- 80 Clinical pharmacology of antiarrhythmic drugs. *H. Neuss*
- 89 Discussion: *Bjerregaard, Mogensen, Neuss, Olsson, Pool, Schlepper, Touboul, Van Durme, Weser*
- 92 Evaluation of chronic antiarrhythmic therapy. *J.-P. Van Durme*
- 95 Discussion: *Johansson, Kulbertus, Pool, Slama, Van Durme, Vedin, Winkle*
- 97 Models for testing of antiarrhythmic drugs. *R.W.F. Campbell*
- 101 Discussion: *Campbell, Chamberlain*
- 102 Management of supraventricular tachyarrhythmias. *C. Lidell*
- 108 Discussion: *Bjerregaard, Campbell, Cerqueira Gomes, Chamberlain, Johansson, Lidell, Mogensen, Olsson, Rasmussen, Sandøe*
- 110 Management of ventricular tachyarrhythmias. *D.E. Jewitt*
- 114 Discussion: *Chamberlain, Jewitt, Kulbertus*
- 116 Management of bradyarrhythmias. *D.B. Shaw*
- 119 Discussion: *Chamberlain, Johansson, Sandøe, Shaw, Van Durme*

121 **In-hospital management of arrhythmias – an impromptu discussion**

Chairmen: *R.W.F. Campbell, D.E. Jewitt, R. Slama and R. Winkle*

122 Discussion on supraventricular tachycardias, atrial fibrillation and the sick sinus syndrome: *Campbell, Cerqueira Gomes, Chamberlain, Gmeiner, Jewitt, Kulbertus, Mogensen, Van Durme, Winkle, Slama, Touboul*

129 Discussion on ventricular extrasystoles, recurrent ventricular tachycardia and torsade de pointes: *Campbell, Chamberlain, Jewitt, Kulbertus, Mogensen, Slama, Touboul, Van Durme, Vedin, Winkle*

135 **Terminology of cardiac arrhythmias**

136 Comments on the definition and classification of cardiac arrhythmias. *E.O. Robles de Medina*

139 **Cardiac arrhythmias in the active population – management recommendations**

Editors: *D.A. Chamberlain, H. Kulbertus, L. Mogensen and M. Schlepfer*